Skip to main content
. 2014 Feb 11;99(5):1694–1700. doi: 10.1210/jc.2013-4440

Figure 2.

Figure 2.

Mean percent change (SEM) in BMD from baseline to 24 months in the lumbar spine (A), one-third distal radius (B), femoral neck (C), and total hip (D) in the teriparatide (TPTD), denosumab (DMAB), and combination (Combo) groups. *, P < .05 compared with other groups.